key: cord-0956020-hj28q0sl authors: Mohamed, Kawthar; Rezaei, Nima title: COVID-19 pandemic is not the time of trial and error date: 2020-09-14 journal: Am J Emerg Med DOI: 10.1016/j.ajem.2020.09.020 sha: 8d81498abab2df51e316c40cc0f5926a14af594e doc_id: 956020 cord_uid: hj28q0sl nan There is an urgent need for an effective medication against the novel coronavirus disease , as it has and continues to have not only significant clinical and non-clinical impacts but also substantial huge economic and psychosocial impacts that have paralyzed the entire world. The severe acute respiratory coronavirus 2 ( SARS-CoV-2) uses the angiotensinconverting enzyme 2 (ACE2) receptor to infect humans with many pathological mechanisms that lead to a wide range of clinical presentations (1, 2) . As a result, it has taken the lives of more than half a million people and has infected around 13.8 million people worldwide (3). Scientists are the major players that strive for a potent cure in the globe (4) . The fastest route that scientists usually take is the drug repurposing, where the previously known drugs that their safety and pharmacokinetics were tested too are reconsidered for a possible new effect (5). This method not only skips the time-consuming process of drug approval but also gives the chance of predicting the possible side effects of repurposed drugs and drug interactions. The swiftness of the computational or in-silico methods has made them appealing target methods for the drug repurposing world (6) . The computational drug repurposing methods have two main approaches; the target-based and the disease-based approaches (7) . The former one is based on detecting the drugs that suit the selected target based on a machine learning algorithm that predicts the drug-target interactions. In contrast, the latter approach focuses on the characteristics of the different diseases as an aspect to look for the drugs that might be useful for a new disease. Computational drug repurposing has many types of algorithms, target modeling, and drug banks or data sets, which J o u r n a l P r e -p r o o f make it an appropriate method for diverse modalities (8) . If this method was the miracle that can rescue us from the COVID-19 disease, why are we still striving to obtain a convenient prescription? Since the start of this pandemic, three eminent clinical studies have been published, but Moreover, Shi and colleagues introduced Adapalene and Fluspirilene as cyclin-dependent kinase 2 (CDK2) inhibitors in colon and liver cancer, respectively; these drugs were detected by in-silico screening and then validated in vitro and in vivo (14) (15) (16) Hence, we would like to suggest some of the promising drugs that the computational drug repurposing has introduced, and can serve as potential candidates for the upcoming clinical trials. In our recent systematic review, we came across Atazanavir, Dolutegravir, and Efavirenz as multi-target drugs that target six viral proteins and Darunavir, Raltegravir, Ritonavir, and Grazoprevir as multi-target drugs that target five viral proteins (12) . What makes the multitarget therapeutic agents better than mono-target drugs is their greater predictive pharmacokinetics, better patient compliance, and reduced risk of drug interactions (17) . Concurrently hitting different targets is, in particular, advantageous for the individuals that express intrinsic or induced variability in drug response due to the alterations of crucial disease-relevant biological pathways and the activation of compensatory mechanisms (18, 19) In conclusion, it is incredibly critical to follow the results provided by fundamental, experimental, and computational methods in parallel with the clinical approaches (20). The computational methods are rapid and cost-effective and can give a clear perspective of the desirable drugs, whereas, the clinical trials are the powerful tools that certify the use of the drugs. In this manner, computational drug repurposing is a promising predictor of the COVID-19 drug trials; thus, the combination of the computational methods and clinical trials delivers revolutionary influences on the drug discovery phenomena. The involvement of the central nervous system in patients with COVID-19 SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids COVID-19: transmission, prevention, and potential therapeutic opportunities Recent advances in drug repositioning for the discovery of new anti-cancer drugs Computational methods for drug repurposing Drug repurposing: progress, challenges, and recommendationsns A trial of lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19 2020 Remdismivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial 2020 Hydroxychloroquine or Chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Computational Drug Discovery and repurposing for the treatment of COVID-19: A systematic review In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anti-cancer drug for bladder carcinoma In silico identification of potential targets and drugs for non-small cell lung cancer In silico identification and in vitro and in vivo validation of anti-psychotic drug fluspirilene as a potential CDK2 inhibitor and a candidate anti-cancer drug Adapalene inhibits the activity of cyclindependent kinase 2 in colorectal carcinoma Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug discovery today Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annual review of pharmacology and toxicology